Role of Presenilin-1 in Aggressive Human Melanoma
Abstract
:1. Introduction
2. Results
2.1. PS-1 Expression Was Lower in Aggressive Melanoma Cells with Active Wnt Signaling
2.2. PS-1 Expression Was Significantly Lower in Advanced-Stage Than in Early-Stage Melanoma
2.3. Inhibition of γ-Secretase in Aggressive Melanoma Cells Led to Increased PS-1 Expression and Decreased Wnt Activity
2.4. Increased PS-1 Expression in DAPT-Treated Aggressive Melanoma Cells Was Associated with Reduced Cell Migration
3. Discussion
4. Materials and Methods
4.1. Cell Cultures
4.2. Serial Coculture
4.3. Western Blotting
4.4. Drug Treatment
4.5. Immunohistochemistry
4.6. Migration Assay
4.7. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Eddy, K.; Shah, R.; Chen, S. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Front. Oncol. 2020, 10, 626129. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Sheikh, M.S. Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol. Cell. Pharmacol. 2014, 6, 228. [Google Scholar] [PubMed]
- Leonardi, G.C.; Falzone, L.; Salemi, R.; Zanghi, A.; Spandidos, D.A.; McCubrey, J.A.; Candido, S.; Libra, M. Cutaneous melanoma: From pathogenesis to therapy (Review). Int. J. Oncol. 2018, 52, 1071–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gilchrest, B.A.; Eller, M.S.; Geller, A.C.; Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med. 1999, 340, 1341–1348. [Google Scholar] [CrossRef]
- Guo, W.; Wang, H.; Li, C. Signal pathways of melanoma and targeted therapy. Signal Transduct. Target. Ther. 2021, 6, 424. [Google Scholar] [CrossRef]
- Sandru, F.; Dumitrascu, M.C.; Petca, A.; Carsote, M.; Petca, R.C.; Ghemigian, A. Melanoma in patients with Li-Fraumeni syndrome (Review). Exp. Ther. Med. 2022, 23, 75. [Google Scholar] [CrossRef]
- Hoek, K.S.; Eichhoff, O.M.; Schlegel, N.C.; Dobbeling, U.; Kobert, N.; Schaerer, L.; Hemmi, S.; Dummer, R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008, 68, 650–656. [Google Scholar] [CrossRef] [Green Version]
- Lim, S.Y.; Menzies, A.M.; Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 2017, 123, 2118–2129. [Google Scholar] [CrossRef] [Green Version]
- Ibler, E.; Tran, G.; Orrell, K.A.; Serrano, L.; Majewski, S.; Sable, K.A.; Thiede, R.; Laumann, A.E.; West, D.P.; Nardone, B. Inverse association for diagnosis of Alzheimer’s disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1893–1896. [Google Scholar] [CrossRef]
- Shafi, O. Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: A systematic review. BMC Neurol. 2016, 16, 236. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Zhang, M.; Cai, F.; Song, W. Biological function of Presenilin and its role in AD pathogenesis. Transl. Neurodegener. 2013, 2, 15. [Google Scholar] [CrossRef] [Green Version]
- Wong, E.; Frost, G.R.; Li, Y.M. gamma-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors. Front. Aging Neurosci. 2020, 12, 614690. [Google Scholar] [CrossRef]
- Sogorb-Esteve, A.; Garcia-Ayllon, M.S.; Llansola, M.; Felipo, V.; Blennow, K.; Saez-Valero, J. Inhibition of gamma-Secretase Leads to an Increase in Presenilin-1. Mol. Neurobiol. 2018, 55, 5047–5058. [Google Scholar] [CrossRef] [Green Version]
- Altmann, A.; Scelsi, M.A.; Shoai, M.; de Silva, E.; Aksman, L.M.; Cash, D.M.; Hardy, J.; Schott, J.M. A comprehensive analysis of methods for assessing polygenic burden on Alzheimer’s disease pathology and risk beyond APOE. Brain Commun. 2020, 2, fcz047. [Google Scholar] [CrossRef]
- Hu, M.; Wang, J. Identification of Hub Genes and Immune Cell Infiltration Characteristics in Alzheimer’s Disease. J. Healthc. Eng. 2021, 2021, 7036194. [Google Scholar] [CrossRef]
- Soriano, S.; Kang, D.E.; Fu, M.; Pestell, R.; Chevallier, N.; Zheng, H.; Koo, E.H. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J. Cell Biol. 2001, 152, 785–794. [Google Scholar] [CrossRef] [Green Version]
- Yang, W.; Wu, P.F.; Ma, J.X.; Liao, M.J.; Xu, L.S.; Xu, M.H.; Yi, L. Presenilin1 exerts antiproliferative effects by repressing the Wnt/beta-catenin pathway in glioblastoma. Cell Commun. Signal. 2020, 18, 22. [Google Scholar] [CrossRef] [Green Version]
- Kang, D.E.; Soriano, S.; Frosch, M.P.; Collins, T.; Naruse, S.; Sisodia, S.S.; Leibowitz, G.; Levine, F.; Koo, E.H. Presenilin 1 facilitates the constitutive turnover of beta-catenin: Differential activity of Alzheimer’s disease-linked PS1 mutants in the beta-catenin-signaling pathway. J. Neurosci. 1999, 19, 4229–4237. [Google Scholar] [CrossRef]
- Kang, D.E.; Soriano, S.; Xia, X.; Eberhart, C.G.; De Strooper, B.; Zheng, H.; Koo, E.H. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: Implications for beta-catenin activation in tumorigenesis. Cell 2002, 110, 751–762. [Google Scholar] [CrossRef] [Green Version]
- Amit, S.; Hatzubai, A.; Birman, Y.; Andersen, J.S.; Ben-Shushan, E.; Mann, M.; Ben-Neriah, Y.; Alkalay, I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: A molecular switch for the Wnt pathway. Genes Dev. 2002, 16, 1066–1076. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Li, Y.; Semenov, M.; Han, C.; Baeg, G.H.; Tan, Y.; Zhang, Z.; Lin, X.; He, X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108, 837–847. [Google Scholar] [CrossRef] [Green Version]
- Hart, M.; Concordet, J.P.; Lassot, I.; Albert, I.; del los Santos, R.; Durand, H.; Perret, C.; Rubinfeld, B.; Margottin, F.; Benarous, R.; et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 1999, 9, 207–210. [Google Scholar] [CrossRef] [Green Version]
- Daugherty, R.L.; Gottardi, C.J. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology 2007, 22, 303–309. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.; Xiao, Q.; Xiao, J.; Niu, C.; Li, Y.; Zhang, X.; Zhou, Z.; Shu, G.; Yin, G. Wnt/beta-catenin signalling: Function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target. Ther. 2022, 7, 3. [Google Scholar] [CrossRef]
- Komiya, Y.; Habas, R. Wnt signal transduction pathways. Organogenesis 2008, 4, 68–75. [Google Scholar] [CrossRef] [Green Version]
- Sinnberg, T.; Levesque, M.P.; Krochmann, J.; Cheng, P.F.; Ikenberg, K.; Meraz-Torres, F.; Niessner, H.; Garbe, C.; Busch, C. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Mol. Cancer 2018, 17, 59. [Google Scholar] [CrossRef] [Green Version]
- Damsky, W.E.; Curley, D.P.; Santhanakrishnan, M.; Rosenbaum, L.E.; Platt, J.T.; Gould Rothberg, B.E.; Taketo, M.M.; Dankort, D.; Rimm, D.L.; McMahon, M.; et al. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20, 741–754. [Google Scholar] [CrossRef] [Green Version]
- Zhou, Y.X.; Wang, X.; Pang, D.Q.; Wang, Y.M.; Bai, J.; Tian, F.; Han, D.; Shi, S.; Hu, L. Nomogram Incorporating the WNT/beta-Catenin Signaling Pathway for Predicting the Survival of Cutaneous Melanoma. Int. J. Genet. Med. 2021, 14, 2751–2761. [Google Scholar] [CrossRef]
- Tai, D.; Wells, K.; Arcaroli, J.; Vanderbilt, C.; Aisner, D.L.; Messersmith, W.A.; Lieu, C.H. Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist 2015, 20, 1189–1198. [Google Scholar] [CrossRef] [Green Version]
- Jung, Y.S.; Park, J.I. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. Exp. Mol. Med. 2020, 52, 183–191. [Google Scholar] [CrossRef] [Green Version]
- Xia, X.; Qian, S.; Soriano, S.; Wu, Y.; Fletcher, A.M.; Wang, X.J.; Koo, E.H.; Wu, X.; Zheng, H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 10863–10868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peltonen, H.M.; Haapasalo, A.; Hiltunen, M.; Kataja, V.; Kosma, V.M.; Mannermaa, A. Gamma-secretase components as predictors of breast cancer outcome. PLoS ONE 2013, 8, e79249. [Google Scholar] [CrossRef] [Green Version]
- Untiveros, G.; Dezi, L.; Gillette, M.; Sidor, J.; Strizzi, L. Normal Skin Cells Increase Aggressiveness of Cutaneous Melanoma by Promoting Epithelial-to-Mesenchymal Transition via Nodal and Wnt Activity. Int. J. Mol. Sci. 2021, 22, 1719. [Google Scholar] [CrossRef]
- Lee, M.K.; Slunt, H.H.; Martin, L.J.; Thinakaran, G.; Kim, G.; Gandy, S.E.; Seeger, M.; Koo, E.; Price, D.L.; Sisodia, S.S. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J. Neurosci. 1996, 16, 7513–7525. [Google Scholar] [CrossRef] [Green Version]
- Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349, 704–706. [Google Scholar] [CrossRef]
- De Strooper, B.; Saftig, P.; Craessaerts, K.; Vanderstichele, H.; Guhde, G.; Annaert, W.; Von Figura, K.; Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391, 387–390. [Google Scholar] [CrossRef]
- Li, P.; Lin, X.; Zhang, J.R.; Li, Y.; Lu, J.; Huang, F.C.; Zheng, C.H.; Xie, J.W.; Wang, J.B.; Huang, C.M. The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer. Oncotarget 2016, 7, 10650–10662. [Google Scholar] [CrossRef] [Green Version]
- Shang, S.; Hua, F.; Hu, Z.W. The regulation of beta-catenin activity and function in cancer: Therapeutic opportunities. Oncotarget 2017, 8, 33972–33989. [Google Scholar] [CrossRef] [Green Version]
- Keyghobadi, F.; Mehdipour, M.; Nekoukar, V.; Firouzi, J.; Kheimeh, A.; Nobakht Lahrood, F.; Azimian Zavareh, V.; Azimi, M.; Mohammadi, M.; Sodeifi, N.; et al. Long-Term Inhibition of Notch in A-375 Melanoma Cells Enhances Tumor Growth Through the Enhancement of AXIN1, CSNK2A3, and CEBPA2 as Intermediate Genes in Wnt and Notch Pathways. Front. Oncol. 2020, 10, 531. [Google Scholar] [CrossRef]
- Gogoi, D.; Dar, A.A.; Chiplunkar, S.V. Involvement of Notch in activation and effector functions of gammadelta T cells. J. Immunol. 2014, 192, 2054–2062. [Google Scholar] [CrossRef]
- Hadland, B.K.; Manley, N.R.; Su, D.; Longmore, G.D.; Moore, C.L.; Wolfe, M.S.; Schroeter, E.H.; Kopan, R. Gamma -secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. USA 2001, 98, 7487–7491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ran, Y.; Hossain, F.; Pannuti, A.; Lessard, C.B.; Ladd, G.Z.; Jung, J.I.; Minter, L.M.; Osborne, B.A.; Miele, L.; Golde, T.E. gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol. Med. 2017, 9, 950–966. [Google Scholar] [CrossRef] [PubMed]
- Cook, N.; Basu, B.; Smith, D.M.; Gopinathan, A.; Evans, J.; Steward, W.P.; Palmer, D.; Propper, D.; Venugopal, B.; Hategan, M.; et al. A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br. J. Cancer 2018, 118, 793–801. [Google Scholar] [CrossRef] [PubMed]
- Krop, I.; Demuth, T.; Guthrie, T.; Wen, P.Y.; Mason, W.P.; Chinnaiyan, P.; Butowski, N.; Groves, M.D.; Kesari, S.; Freedman, S.J.; et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 2012, 30, 2307–2313. [Google Scholar] [CrossRef]
- Daraghma, H.; Untiveros, G.; Raskind, A.; Iaccarino, E.; Sandomenico, A.; Ruvo, M.; Arnouk, H.; Ciancio, M.J.; Cuevas-Nunez, M.; Strizzi, L. The role of Nodal and Cripto-1 in human oral squamous cell carcinoma. Oral Dis. 2021, 27, 1137–1147. [Google Scholar] [CrossRef]
- Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Barsouk, A. Epidemiology of Melanoma. Med. Sci. 2021, 9, 63. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sidor, J.; Gillette, M.; Dezi, L.A.; Untiveros, G.; Strizzi, L. Role of Presenilin-1 in Aggressive Human Melanoma. Int. J. Mol. Sci. 2022, 23, 4904. https://doi.org/10.3390/ijms23094904
Sidor J, Gillette M, Dezi LA, Untiveros G, Strizzi L. Role of Presenilin-1 in Aggressive Human Melanoma. International Journal of Molecular Sciences. 2022; 23(9):4904. https://doi.org/10.3390/ijms23094904
Chicago/Turabian StyleSidor, Julia, Megan Gillette, Lindsay Ann Dezi, Gustavo Untiveros, and Luigi Strizzi. 2022. "Role of Presenilin-1 in Aggressive Human Melanoma" International Journal of Molecular Sciences 23, no. 9: 4904. https://doi.org/10.3390/ijms23094904